ICMR Study on 1.6 Lakh Patients Reveals: Common Infections Turning Fatal as Last-Resort Drugs Fail
_1268760962.jpg)
In a grim wake-up call for public health systems, a comprehensive new study published in The Lancet Regional Health - South-East Asia by the Indian Council of Medical Research (ICMR) has revealed that antimicrobial resistance (AMR) has emerged as a critical health crisis in India. Analyzing extensive clinical data from 20 major hospitals across the nation, the research underscores that common bacterial infections are increasingly defying standard treatments, driving up mortality rates, doubling medical expenditures, and turning previously manageable illnesses into life-threatening emergencies.
Landmark ICMR Study Uncovers High Resistance in Gram-Negative Bacteria
The comprehensive ICMR investigation evaluated medical records from approximately 1.6 lakh patients admitted to premier hospitals between April 2022 and 2025. Among the cohort, over 26,000 patients were infected with dangerous Gram-negative bacteria such as E. coli. Most alarmingly, 61.1 percent of these infections proved to be carbapenem-resistant. Carbapenem antibiotics have long stood as the ultimate last-resort defense for treating severe, complicated infections; however, widespread and indiscriminate usage has fueled unprecedented drug resistance, rendering even these powerful medicines ineffective against mutating pathogens.
Skyrocketing Mortality Rates and Escalating Financial Burdens
The clinical consequences of drug-resistant pathogens are starkly reflected in patient survival outcomes and hospital bills:
Higher Mortality in E. coli: Patients infected with drug-resistant E. coli suffered a mortality rate of 24.4 percent, compared to 17.3 percent for those with non-resistant strains.
Severe Risk in K. pneumoniae: Mortality rates for K. pneumoniae resistant infections climbed to 31.2 percent, significantly higher than the 23.5 percent recorded for common infections.
Doubled Treatment Costs: Treating antimicrobial-resistant E. coli infections required an average expenditure of $420, roughly double the $211 cost associated with standard infections, driven by the necessity of administering multiple high-cost reserve drugs simultaneously.
Furthermore, because identifying resistant strains through bacterial culturing takes precious days, patients suffering from AMR experience prolonged hospital stays, intensifying the physical, emotional, and financial toll on families.
Experts Warn Against Over-Reliance on New Drug Development
Dr. Kamini Walia, a senior scientist at ICMR and co-author of the landmark study, emphasized that antimicrobial resistance is no longer a distant theoretical threat but an active, present-day crisis claiming Indian lives daily. Experts stress that simply manufacturing new generations of antibiotics will not solve the crisis. Curbing the escalating AMR pandemic demands strict clinical stewardship, early and precise diagnostic testing, rigorous hospital infection control protocols, and absolute restraint in the irrational consumption of broad-spectrum antibiotics.
_1268760962_351x234.jpg)
_1811183371_351x234.jpg)
_449735133_351x234.jpg)
_1287224325_351x234.jpg)
